Wantai Biopharm (603392) announced on the evening of September 9 that the nasal spray influenza virus vector COVID-19 vaccine, which was jointly developed by the company, Xiamen University, and the University of Hong Kong, had recently received the notification of acceptance of the clinical trial application and the clinical trial approval from the National Medical Products Administration, and the product was granted for the clinical trial right. The approval was valid for 12 months. In accordance with the requirements of the clinical trial approval, the company has initiated a phase I clinical study.
Founded in 1991, Wantai BioPharm is a high-tech enterprise engaged in the research, development, and production of biological diagnostic reagents and vaccines.
